In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...

Regarding efficacy, the phase 1 trial showed impressive objective response rates (ORR), approaching 70%. Typical PRRT alone ...

A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.

Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage ...

The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...

The combination of talquetamab (Talvey) and daratumumab (Darzalex) demonstrated promising and robust clinical activity for the treatment of patients with heavily pretreated, relapsed/refractory ...

1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...

Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with ...

Lifileucel shows a 25.6% objective response rate and 71.8% disease control rate in advanced nonsquamous NSCLC patients, ...

The regimen of bexmarilimab and azacitidine (Vidaza) demonstrated a highly promising efficacy profile with a manageable ...

While impressive efficacy was seen in both cohorts, Dr Strosberg reiterates the importance of a randomized study to confirm ...

Camizestrant combined with CDK4/6 inhibitors shows antitumor activity and is well-tolerated in ER+, HER2– advanced breast ...